Novartis grants milestone payment to Cadent for Phase 2 MIJ821 trial
Category: #health  By Mateen Dalal  Date: 2019-05-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novartis grants milestone payment to Cadent for Phase 2 MIJ821 trial

MIJ821 is a potent and selective NMDA receptor modulator being developed for the treatment of treatment-resistant depression

Cadent Therapeutics, a precision neuroscience company, has recently announced that it has received the second milestone payment from Swiss multinational pharmaceutical company Novartis, after commencing a Phase 2 clinical study of MIJ821 in development for treatment-resistant depression (TRD).

Reportedly, MIJ821 is a subtype selective NMDA receptor negative allosteric modulator (NAM). Cadent is focused on the development of therapies to recover the lives of patients who suffer from cognitive and movement disorders.

According to Chief Executive Officer of Cadent Therapeutics, Jodie Morrison, Novartis has advanced MIJ821 to the next step of clinical development. MIJ821 is a potent and selective NMDA receptor modulator that company believes would take both a differentiated and important position in the treatment of treatment-resistant depression by developing on the certified mechanism of NMDAr modulation, Morrison said.

Sources close to the matter informed that Cadent Therapeutics had licensed the intellectual property for compounds that selectively modulate NR2B-carrying NMDA receptors to Novartis exclusively. MIJ821 (CAD-9271) was included in the license. For the program, Novartis is responsible for all research and development.

For the uninitiated, Cadent Therapeutics is involved in generating therapies for the treatment of cognitive impairment and movement disorders. The company combines patient selection, novel quantitative endpoints, target specificity, and drug design and optimization to generate first-in-class molecules to treat cognitive disorders and movement.

Supposedly, the company is swiftly advancing its portfolio of positive allosteric modulators to treat schizophrenia, essential tremor, and spinocerebellar ataxia. The company has an absolute license and partnership agreement with Novartis to develop a negative allosteric modulator (NAM), which now under Phase 1 clinical studies for the treatment of treatment-resistant depression (TRD).

Sources mentioned that investors in the company include Slater Technology Fund, Qiming Venture Partners, Access Industries, Atlas Venture, Cowen Healthcare Investments, Clal Biotechnology Industries and Novartis Institutes for Biomedical Research.

Source Credit: http://www.cadenttx.com/2019/05/23/cadent-receives-milestone-payment-for-initiation-of-phase-2-trial-of-mij821-in-treatment-resistant-depression/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

MoA Technology targets herbicide resistance crisis & raises $8 million
MoA Technology targets herbicide resistance crisis & raises $8 million
By Mateen Dalal

MoA Technology has created three platforms: MoA SELECTTM, MoA TARGETTM and MoA GALAXYTM, which would work together for effective herbicide creation.   MoA Technology is borne out of Oxford University research is aimed at inhibiting herbicide...

Trump refuses to forge deals with Huawei citing national security
Trump refuses to forge deals with Huawei citing national security
By Mateen Dalal

Donald Trump declares the business with Huawei as a national threat and hence forth has declined all the business opportunities with the company.   The existing contract of the Commerce Department is expected to end sooner. The United Stat...

Trovagene to unveil key study data at APAC Prostate Cancer Conference
Trovagene to unveil key study data at APAC Prostate Cancer Conference
By Mateen Dalal

Data from the Phase 2 Onvansertib clinical trial will be presented at the 20th Prostate Cancer Conference.   The trial assesses the efficacies of Onvansertib on patients with Metastatic Castration-Resistant Prostate Cancer. Trovagene, a cl...